Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Saci-IO HR+: Randomized Phase II Study of Sacituzumab Govitecan With or Without Pembrolizumab in Hormone Receptor-positive (HR+) / HER2- Metastatic Breast Cancer (MBC)

NCT04448886 is registered in ClinicalTrials.gov with Ana C Garrido-Castro, MD as lead sponsor.

NCT NCT04448886
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04448886 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Saci-IO HR+: Randomized Phase II Study of Sacituzumab Govitecan With or Without Pembrolizumab in Hormone Receptor-positive (HR+) / HER2- Metastatic Breast Cancer (MBC)
Lead sponsor
Ana C Garrido-Castro, MD
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 23, 2020
Completion date
June 1, 2027
Enrollment
110 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

her2-negative breast cancer, hr-positive breast cancer, invasive breast cancer, metastatic breast cancer